ArticleBrain and behavior2025
Impact of Treatment Delay and Prognostic Factors in Acute Myelitis of Neuromyelitis Optica Spectrum Disease.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ravulizumab for relapse prevention in AQP4-IgG-positive neuromyelitis optica spectrum disorder: a 2-year follow-up case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the relationship between treatment delay and poor prognosis in acute myelitis of Neuromyelitis Optica Spectrum Disorder (NMOSD). Additionally, we seek to explore the related factors that contribute to poor prognosis, with the intention of providing more precise clinical guidance.
methodsWe retrospectively analyzed the acute myelitis attacks of NMOSD patients who were continuously followed up or referred to our hospital from January 2018 to September 2022. We further calculated the proportion of clinical score improvement: (acute-follow-up)/(acute-baseline); poor prognosis was assigned to 0%-33% improvement. The relationship between treatment delay and poor prognosis was evaluated with clustered Receiver Operating Characteristic (ROC) analysis. A Generalized linear mixed model was used to analyze the related factors.
resultsThis study included a total of 144 episodes of myelitis attacks, of which 21.5% (31/144) resulted in poor prognosis. Based on the results of the clustered ROC analysis, it has been determined that treatment delay holds significant predictive value for poor prognosis (p = 0.001), with the optimal cut-off point being 15 days. The generalized linear mixed model revealed that factors contributing to poor prognosis in NMOSD myelitis include age (OR, 1.041; CI, 1.013-1.071; p = 0.004) and treatment delay (OR, 1.034; CI, 1.014-1.054; p = 0.001).
conclusionOur results confirm the treatment delay and age as predictors of poor prognosis in acute myelitis of NMOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.